Aclaris Therapeutics Inc (ACRS)
16.76
-0.04 (-0.24%)
USD |
NASDAQ |
Aug 15, 16:00
16.78
+0.02 (+0.09%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.117B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.86% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 170.52 |
| Price to Book Value | 4.740 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.73% |
News
Headline
Wire
Time (ET)
Globe Newswire
08/03 07:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/02/2022* | -- | Results | Q3 2022 | -- | -0.41 | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.31 | -0.36 | 14.48% | |
| 05/10/2022 | -- | Results | Q1 2022 | -0.31 | -0.41 | 24.85% | |
| 02/24/2022 | -- | Results | Q4 2021 | -0.37 | -0.36 | -2.07% | |
| 11/02/2021 | -- | Results | Q3 2021 | -0.35 | -0.28 | -25.00% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.34 | -0.28 | -21.43% | |
| 05/07/2021 | -- | Results | Q1 2021 | -0.57 | -0.28 | -103.6% | |
| 02/25/2021 | -- | Results | Q4 2020 | -0.31 | -0.26 | -19.96% |
*Estimated Date/Time
Earnings
Profile
Edit
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |
| URL | https://www.aclaristx.com |
| Investor Relations URL | https://www.aclaristx.com/#!investors/juser |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 02, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 15, 2022.
Fundamentals
| Revenue (TTM) | 6.141M |
| Total Expenses (TTM) | 90.73M |
| Net Income (TTM) | -83.27M |
| Total Assets (Quarterly) | 277.98M |
| Total Liabilities (Quarterly) | 42.22M |
| Shareholders Equity (Quarterly) | 235.75M |
| Cash from Operations (TTM) | -68.32M |
| Cash from Investing (TTM) | -38.14M |
| Cash from Financing (TTM) | 61.27M |
Ratings
Profile
Edit
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |
| URL | https://www.aclaristx.com |
| Investor Relations URL | https://www.aclaristx.com/#!investors/juser |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 02, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ACRS Tweets |